Pages

Monday, 16 December 2013

Can A Brain Tumor Become Helped By The ICT-107 Vaccine

----------------------------------------------
------------------------------------------------------------------

By Rob Sutter


Brain tumor awareness is home to a number of different therapies, which goes without saying. It seems as though these particular growths are going to be targeted in the best of ways, specialists being able to assess what can be done in order to help them. This is where the ICT-107 can come into play and it was one that was spoken about in a recent report. From what I have picked up on, it is the kind of report that is more than worth talking about.

An article on Medical News Today went into detail about this particular matter and I do not think that it is hard to see why. Keep in mind that glioblastoma multiforme is the condition being targeted here, which is something that can be said about most other procedures related to brain tumor awareness. The level of aggression seen in this particular condition is something that no other tumor type can match. As a result, organizations along the lines of Voices against Brain Cancer are going to focus on it.

From what I have seen, this condition is one in which the cancerous cells seem to regenerate rather quickly. The cells are ones which feed off of the blood stream in the body, which means that there is a source of nourishment set in place. The American Brain Tumor Association went into detail about this as well as the level of risk that was seen. Even though this condition can come about in anyone, it seems as though said risk increases with men more than women, according to the ABTA.

There was a study done by the Cedars-Sinai Medical Group that would put to use a vaccine referred to as ICT-107. In essence, what this vaccine would do is alert the immune system to the presence of cancerous cells before they would be targeted with a tumor-killing response. Specifically, it would be able to target six different antigens that are responsible for the consistency of these particular growths. Once the typical surgical methods were done, the vaccine would be administered three times a week at two-week intervals.

After this was done, the results of the study showed that seven of the original sixteen patients here were helped tremendous. In particular, they were given lengths of survival ranging from 60.7 to 82.7 months following diagnosis. In addition, six of the people in this original group were deemed "progression-free." What this means is that not only did the tumors not return but there was no further need for treatment after the fact. To say that there was success with this particular method is an understatement.




About the Author:



0 comments:

Post a Comment